Exciting times at BRB! I couldn't be more proud to work alongside this team of brilliant and dedicated people. 💙
Curious to learn more about our First-in-Human Study of BRB-002? Check out our press release here: https://lnkd.in/euhPue-g #BitterrootBio #BRB002 #FirstinHuman #heartdisease #cardiovascular #drugdevelopment
Curious to learn more about our First-in-Human Study of BRB-002? Check out our press release here: https://lnkd.in/euhPue-g #BitterrootBio #BRB002 #FirstinHuman #heartdisease #cardiovascular #drugdevelopment
More than 3,900 patients have been treated in clinical studies with Pantera Lux drug-coated balloon (DCB), investigating coronary DCBs for various indications. Listen to Hee Hwa Ho, who summarizes the benefits of coronary DCBs beyond ISR. Find out more about Pantera Lux and its clinical data 👉 https://ow.ly/8YxY50PY1rf #BIOTRONIK #PanteraLux #WhatWouldYouChoose
The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year:¹ https://bit.ly/49SGIU1 Risk Info: https://bit.ly/3UtKYF2 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN™* platform at 1 year.¹ Explore the evidence: https://bit.ly/3QClH9n Risk Info: https://bit.ly/3WyhSWv TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024
Discover a clinically proven solution for #ThyroidRFA that’s minimally invasive, FDA-cleared, and has been performed on over 100,000 patients worldwide. Learn more about the #STARmed RF System and why it’s been used in over 70% of peer-reviewed thyroid RFA clinical studies(1): https://bit.ly/4dFvaqs (1): Data on File Product Indications: The VIVA combo RF System is FDA-cleared. It is intended for use in percutaneous and intraoperative coagulation and ablation of tissue.
The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/4aryVhk Risk Info: https://bit.ly/49AjEJz TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg http://ow.ly/XzxC105z0m8
Challenge the status quo in Pulmonary Embolism treatment with Thrombolex's innovative technology. The BASHIR™ Endovascular Catheter is elegantly simple, safe, and highly effective. Explore single session pharmacomechanical (PML) therapy at Thrombolex.com #Thrombolex
The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year¹: https://bit.ly/4eb8a31 Risk Info: https://bit.ly/4aKlCI1 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
